Journal
MOLECULAR PHARMACEUTICS
Volume 18, Issue 6, Pages 2285-2297Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.1c00095
Keywords
CCK2R; Pseudomonas exotoxin; immunotoxin; immunotherapy; colorectal malignancies
Funding
- Project of Science and Technology Development Plan of Jilin Province [20200404123YY]
Ask authors/readers for more resources
The study developed a new version of CCK2R-targeting immunotoxin GD9P, which showed higher antitumor activity against human colorectal cancer compared to the parental immunotoxin, suggesting its promising potential for immunotherapy targeting CCK2R-expressing colorectal malignancies.
Cholecystokinin-2 receptor (CCK2R) has been proven to be a specific biomarker for colorectal malignancies. Immunotoxins are a valuable class of immunotherapy agents consisting of a targeting element and a bacterial or plant toxin. Previous work demonstrated that targeting CCK2R is a good therapeutic strategy for the treatment of colorectal cancer (CRC). In the present study, we developed a new version of CCK2R-targeting immunotoxin GD9P using a targeted peptide, GD9, as the binding motif and a truncated Pseudomonas exotoxin A (PE38) as the cytokiller. BALB/c nude mice were treated with different doses of GD9P, and pharmacodynamics, pharmacokinetic, and toxicological data were obtained throughout this study. Compared to the parental immunotoxin rCCK8PE38, GD9P exhibited about 1.5-fold yield, higher fluorescence intensity, and increased antitumor activity against human CRC in vitro and in vivo. The IC50 values of GD9P in vitro ranged from 1.61 to 4.55 nM. Pharmacokinetic studies were conducted in mice with a T-1/2 of 69.315 min. When tumor-bearing nude mice were treated with GD9P at doses >= 2 mg/kg for five doses, a rapid shrinkage in tumor volume and, in some cases, complete remission was observed. A preliminary safety evaluation demonstrated a good safety profile of GD9P as a Pseudomonas exotoxin A-based immunotherapy. The therapy in combination with oxaliplatin can increase the antitumor efficacy and reduce the toxic side effects caused by chemotherapy. In conclusion, the data support the use of GD9P as a promising immunotherapy targeting CCK2R-expressing colorectal malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available